I can't say that you ARE reading it wrong, sosjtb.
"As soon as practicable after payment in full of, or reserve for, all other Allowed Claims, the Liquidating Trust shall pay to each holder of an Allowed Subordinated Claim or an Allowed Existing Equity Interest its pro rata share of any remaining amounts in the Liquidating Trust subject to the terms and conditions of this Combined Plan and Disclosure Statement, the Liquidating Trust Agreement, and the Bankruptcy Code. No distribution to Class 4 (Subordinated Claims) or Class 5 (Existing Equity Interests) is anticipated."
"As soon as practicable after payment in full of, or reserve for, all other Allowed Claims, the Liquidating Trust shall pay to each holder of an Allowed Subordinated Claim or an Allowed Existing Equity Interest its pro rata share of any remaining amounts in the Liquidating Trust subject to the terms and conditions of this Combined Plan and Disclosure Statement, the Liquidating Trust Agreement, and the Bankruptcy Code. No distribution to Class 4 (Subordinated Claims) or Class 5 (Existing Equity Interests) is anticipated...
there is no assurance that the Liquidating Trust will be successful in prosecuting any Cause of Action or generate sufficient proceeds from the Causes of Action for Distribution. "
p 33/65 p 35/65
The case remains a CH11, and the recall of the loaned shares, especially if Novavax purchases the lenz/vaccine cocktail, or we combine/partner/merge through Taran into Sanofi, and get regulatory approval from Australia, perhaps with a PRV, we could easily see Ed Dowd announce a target price of $67 for our shares.